Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 7689254, 9 pages
https://doi.org/10.1155/2017/7689254
Review Article

Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome

Department of Nephrology, University Hospital, Medical Faculty, Heinrich-Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany

Correspondence should be addressed to Lorenz Sellin

Received 28 February 2017; Accepted 12 April 2017; Published 3 May 2017

Academic Editor: Andreas Kronbichler

Copyright © 2017 Eva Königshausen and Lorenz Sellin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis,” Kidney International, vol. 2, supplement 2, pp. 139–274, 2012.
  2. J. Floege and K. Amann, “Primary glomerulonephritides,” The Lancet, vol. 387, no. 10032, pp. 2036–2048, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Ruggenenti, E. Perticucci, P. Cravedi et al., “Role of remission clinics in the longitudinal treatment of CKD,” Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1213–1224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Barbour, A. Greenwald, O. Djurdjev et al., “Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis,” Kidney International, vol. 81, no. 2, pp. 190–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Lee, A. K. Biddle, S. Lionaki et al., “Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy,” Kidney International, vol. 85, no. 6, pp. 1412–1420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. L. H. Beck Jr., R. G. B. Bonegio, G. Lambeau et al., “M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 361, no. 1, pp. 11–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. C. Stanescu, M. Arcos-Burgos, A. Medlar et al., “Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 364, pp. 616–626, 2011. View at Publisher · View at Google Scholar
  8. N. M. Tomas, L. H. Beck Jr., C. Meyer-Schwesinger et al., “Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 371, no. 24, pp. 2277–2287, 2014. View at Publisher · View at Google Scholar
  9. N. Polanco, E. Gutierrez, A. Covarsi et al., “Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 21, pp. 697–704, 2010. View at Publisher · View at Google Scholar
  10. D. C. Cattran, “Toward quantitating the burden of glomerulonephritis in the United States,” Kidney International, vol. 90, no. 4, pp. 732–734, 2016. View at Publisher · View at Google Scholar
  11. L. H. Beck Jr., F. C. Fervenza, D. M. Beck et al., “Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1543–1550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. De Vriese, R. J. Glassock, K. A. Nath, S. Sethi, and F. C. Fervenza, “A Proposal for a serology-based approach to membranous nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 421–430, 2017. View at Publisher · View at Google Scholar
  13. J. M. Hofstra, A. J. W. Branten, J. J. J. M. Wirtz, T. C. Noordzij, P. W. G. Du Buf-Vereijken, and J. F. M. Wetzels, “Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 129–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. J. G. van den Brand, P. R. Van Dijk, J. M. Hofstra, and J. F. M. Wetzels, “Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 150–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Howman, T. L. Chapman, M. M. Langdon et al., “Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial,” The Lancet, vol. 381, no. 9868, pp. 744–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. J. G. van den Brand, P. R. van Dijk, J. M. Hofstra, and J. F. M. Wetzels, “Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1066–1073, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Chen, A. Schieppati, G. Cai et al., “Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 787–796, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ponticelli, P. Passerini, M. Salvadori et al., “A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy,” American Journal of Kidney Diseases, vol. 47, no. 2, pp. 233–240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A.-E. van de Logt, C. H. Beerenhout, H. S. Brink, J. J. Van De Kerkhof, J. F. Wetzels, and J. M. Hofstra, “Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study,” PLoS ONE, vol. 10, no. 11, Article ID e0142033, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Hladunewich, D. Cattran, L. H. Beck et al., “A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 29, no. 8, pp. 1570–1577, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, and P. Ruggenenti, “Rituximab for idiopathic membranous nephropathy,” The Lancet, vol. 360, no. 9337, pp. 923–924, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. F. C. Fervenza, F. G. Cosio, S. B. Erickson et al., “Rituximab treatment of idiopathic membranous nephropathy,” Kidney International, vol. 73, no. 1, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Ruggenenti, P. Cravedi, A. Chianca et al., “Rituximab in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1416–1425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Moroni, F. Depetri, L. Del Vecchio et al., “Low-dose rituximab is poorly effective in patients with primary membranous nephropathy,” Nephrology Dialysis Transplantation, 2016. View at Publisher · View at Google Scholar
  25. K. Dahan, H. Debiec, E. Plaisier et al., “Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up,” Journal of the American Society of Nephrology, vol. 28, no. 1, pp. 348–358, 2017. View at Publisher · View at Google Scholar
  26. F. C. Fervenza, P. A. Canetta, S. J. Barbour et al., “A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (mentor),” Nephron, vol. 130, no. 3, pp. 159–168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Rojas-Rivera, G. Fernández-Juárez, A. Ortiz et al., “A european multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study,” Clinical Kidney Journal, vol. 8, no. 5, pp. 503–510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. D. C. Cattran and P. E. Brenchley, “Membranous nephropathy: integrating basic science into improved clinical management,” Kidney International, vol. 91, no. 3, pp. 566–574, 2017. View at Publisher · View at Google Scholar
  29. J. Müller-Deile, L. Schiffer, M. Hiss, H. Haller, and M. Schiffer, “A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis,” European Journal of Clinical Investigation, vol. 45, no. 12, pp. 1260–1269, 2015. View at Publisher · View at Google Scholar
  30. R. C. Aalberse and J. Schuurman, “IgG4 breaking the rules,” Immunology, vol. 105, no. 1, pp. 9–19, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Roccatello, S. Sciascia, D. Di Simone et al., “New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature,” Autoimmunity Reviews, vol. 15, no. 6, pp. 529–538, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Vivarelli, L. Massella, B. Ruggiero, and F. Emma, “Minimal change disease,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 332–345, 2017. View at Publisher · View at Google Scholar
  33. M. A. Saleem and Y. Kobayashi, “Cell biology and genetics of minimal change disease,” F1000Research, vol. 5, Article 412, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Königshausen and L. Sellin, “Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates,” BioMed Research International, vol. 2016, Article ID 3765608, p. 9, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. R. J. Maas, J. K. Deegens, and J. F. Wetzels, “Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future,” Nephrology Dialysis Transplantation, vol. 29, no. 12, pp. 2207–2216, 2014. View at Publisher · View at Google Scholar
  36. T. Wada and M. Nangaku, “A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues,” Clinical Kidney Journal, vol. 8, no. 6, pp. 708–715, 2015. View at Publisher · View at Google Scholar
  37. R. J. Shalhoub, “Pathogenesis of lipoid nephrosis: a disorder of T cell function,” The Lancet, vol. 2, no. 7880, pp. 556–560, 1974. View at Google Scholar · View at Scopus
  38. V. Elie, M. Fakhoury, G. Deschênes, and E. Jacqz-Aigrain, “Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives,” Pediatric Nephrology, vol. 27, no. 8, pp. 1249–1256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Sahali, K. Sendeyo, M. Mangier et al., “Immunopathogenesis of idiopathic nephrotic syndrome with relapse,” Seminars in Immunopathology, vol. 36, no. 4, pp. 421–429, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Colucci, R. Carsetti, S. Cascioli et al., “B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 27, no. 6, pp. 1811–1822, 2016. View at Publisher · View at Google Scholar
  41. B. Basu, “Ofatumumab for rituximab-resistant nephrotic syndrome,” The New England Journal of Medicine, vol. 370, no. 13, pp. 1268–1270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Fornoni, J. Sageshima, C. Wei et al., “Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis,” Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A.-L. Sellier-Leclerc, V. Baudouin, T. Kwon et al., “Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery,” Nephrology Dialysis Transplantation, vol. 27, no. 3, pp. 1083–1089, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. E. M. Hodson, N. S. Willis, and J. C. Craig, “Corticosteroid therapy for nephrotic syndrome in children,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD001533, 2007. View at Google Scholar · View at Scopus
  45. K.-C. Tse, M.-F. Lam, P.-S. Yip et al., “Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses,” Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1316–1320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Nolasco, J. S. Cameron, E. F. Heywood, J. Hicks, C. Ogg, and D. G. Williams, “Adult-onset minimal change nephrotic syndrome: a long-term follow-up,” Kidney International, vol. 29, no. 6, pp. 1215–1223, 1986. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Waldman, R. J. Crew, A. Valeri et al., “Adult minimal-change disease: clinical characteristics, treatment, and outcomes,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 3, pp. 445–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. K. Mak, C. D. Short, and N. P. Mallick, “Long-term outcome of adult-onset minimal-change nephropathy,” Nephrology Dialysis Transplantation, vol. 11, no. 11, pp. 2192–2201, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Hahn, E. M. Hodson, N. S. Willis, and J. C. Craig, “Corticosteroid therapy for nephrotic syndrome in children,” The Cochrane Database of Systematic Reviews, no. 3, Article ID CD001533, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Iijima, D. M. Sako, K. Nozu et al., “Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial,” The Lancet, vol. 384, no. 9950, pp. 1273–1281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Ravani, R. Rossi, A. Bonanni et al., “Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial,” Journal of the American Society of Nephrology, vol. 26, no. 9, pp. 2259–2266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Munyentwali, K. Bouachi, V. Audard et al., “Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease,” Kidney International, vol. 83, no. 3, pp. 511–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Guitard, A.-L. Hebral, F. Fakhouri et al., “Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance,” Nephrology, Dialysis, Transplantation, vol. 29, no. 11, pp. 2084–2091, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Takei, M. Itabashi, T. Moriyama et al., “Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults,” Nephrology Dialysis Transplantation, vol. 28, no. 5, pp. 1225–1232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Iwabuchi, T. Takei, T. Moriyama, M. Itabashi, and K. Nitta, “Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment,” Medicine (Baltimore), vol. 93, no. 29, Article e300, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Ruggenenti, B. Ruggiero, P. Cravedi et al., “Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 25, no. 4, pp. 850–863, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Madan, S. Mijovic-Das, A. Stankovic, G. Teehan, A. S. Milward, and A. Khastgir, “Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series,” BMC Nephrology, vol. 17, no. 1, Article 37, 2016. View at Publisher · View at Google Scholar
  58. S. S. Chugh, L. C. Clement, and C. Macé, “New insights into human minimal change disease: lessons from animal models,” American Journal of Kidney Diseases, vol. 59, no. 2, pp. 284–292, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. L. C. Clement, C. Avila-Casado, C. Macé et al., “Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome,” Nature Medicine, vol. 17, no. 1, pp. 117–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. S. S. Chugh, C. Macé, L. C. Clement, M. D. N. Avila, and C. B. Marshall, “Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease,” Frontiers in Pharmacology, vol. 5, Article 23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Agrawal, M. A. Chanley, D. Westbrook et al., “Pioglitazone enhances the beneficial effects of glucocorticoids in experimental nephrotic syndrome,” Scientific Reports, vol. 6, Article ID 24392, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Tian and S. Ishibe, “Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease,” Nephrology Dialysis Transplantation, vol. 31, no. 10, pp. 1577–1583, 2016. View at Publisher · View at Google Scholar
  63. M. Schiffer, B. Teng, C. Gu et al., “Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models,” Nature Medicine, vol. 21, no. 6, pp. 601–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. A. J. Collins, R. N. Foley, C. Herzog et al., “US renal data system 2010 annual data report,” American Journal of Kidney Diseases, vol. 55, no. 1, p. A8, e1-526, 2011. View at Publisher · View at Google Scholar
  65. V. D. D'Agati, F. J. Kaskel, and R. J. Falk, “Focal segmental glomerulosclerosis,” The New England Journal of Medicine, vol. 365, no. 25, pp. 2398–2411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. V. D. D'Agati, A. B. Fogo, J. A. Bruijn, and J. C. Jennette, “Pathologic classification of focal segmental glomerulosclerosis: a working proposal,” The American Journal of Kidney Diseases, vol. 43, no. 2, pp. 368–382, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. A. B. Fogo, “Causes and pathogenesis of focal segmental glomerulosclerosis,” Nature Reviews Nephrology, vol. 11, no. 2, pp. 76–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Ponticelli, G. Rizzoni, A. Edefonti et al., “A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome,” Kidney International, vol. 43, no. 6, pp. 1377–1384, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Braun, F. Schmutzler, C. Lange et al., “Immunosuppressive treatment for focal segmental glomerulosclerosis in adults,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003233, 2008. View at Google Scholar · View at Scopus
  70. D. C. Cattran, G. B. Appel, L. A. Hebert et al., “A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group,” Kidney International, vol. 56, no. 6, pp. 2220–2226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Duncan, A. Dhaygude, J. Owen et al., “Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy,” Nephrology Dialysis Transplantation, vol. 19, no. 12, pp. 3062–3067, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Segarra, J. Vila, L. Pou et al., “Combined therapy oftacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up,” Nephrology Dialysis Transplantation, vol. 17, no. 4, pp. 655–662, 2002. View at Publisher · View at Google Scholar
  73. L.-P. Laurin, A. M. Gasim, C. J. Poulton et al., “Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 386–394, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Ren, P. Shen, X. Li, X. Pan, W. Zhang, and N. Chen, “Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial,” American Journal of Nephrology, vol. 37, no. 1, pp. 84–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Ramachandran, V. Kumar, M. Rathi et al., “Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience,” Nephrology Dialysis Transplantation, vol. 29, no. 10, pp. 1918–1924, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Fernandez-Fresnedo, A. Segarra, E. González et al., “Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1317–1323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Kronbichler and A. Bruchfeld, “Rituximab in adult minimal change disease and focal segmental glomerulosclerosis,” Nephron—Clinical Practice, vol. 128, pp. 277–282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Sgambat, M. Banks, and A. Moudgil, “Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 28, no. 11, pp. 2131–2135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Kopač, A. Meglič, and R. R. Rus, “Partial remission of resistant nephrotic syndrome after oral galactose therapy,” Therapeutic Apheresis and Dialysis, vol. 15, no. 3, pp. 269–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. E. De Smet, J.-P. Rioux, H. Ammann, C. Déziel, and S. Quérin, “FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 9, pp. 2938–2940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Trachtman, S. Vento, E. Herreshoff et al., “Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group,” BMC Nephrology, vol. 16, article 111, 2015. View at Publisher · View at Google Scholar
  82. C.-C. Yu, A. Fornoni, A. Weins et al., “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2416–2423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Sprenger-Mähr, E. Zitt, A. Soleiman, and K. Lhotta, “Successful treatment of focal segmental glomerulosclerosis after kidney transplantation with plasma exchange and abatacept in a patient with juvenile rheumatoid arthritis,” Case Reports in Transplantation, vol. 2016, Article ID 7137584, 4 pages, 2016. View at Publisher · View at Google Scholar
  84. A. Benigni, E. Gagliardini, and G. Remuzzi, “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 370, no. 13, pp. 1261–1263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. E. H. Garin, J. Reiser, G. Cara-Fuentes et al., “Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 30, no. 3, pp. 469–477, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Delville, E. Baye, A. Durrbach et al., “B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS,” Journal of the American Society of Nephrology, vol. 27, pp. 2520–2527, 2016. View at Google Scholar
  87. T. Kristensen, P. Ivarsen, and J. Povlsen, “Unsuccessful treatment with abatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation,” Case Reports in Nephrology and Dialysis, vol. 7, pp. 1–5, 2017. View at Google Scholar
  88. C. Wang, R. S. Liverman, R. Garro et al., “Ofatumumab for the treatment of childhood nephrotic syndrome,” Pediatric Nephrology, vol. 32, no. 5, pp. 835–841, 2017. View at Publisher · View at Google Scholar
  89. A. Bonanni, R. Rossi, C. Murtas, and G. M. Ghiggeri, “Low-dose ofatumumab for rituximab-resistant nephrotic syndrome,” BMJ Case Reports, vol. 2015, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Vincenti, F. C. Fervenza, K. N. Campbell et al., “A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis,” Kidney International Reports, 2017. View at Publisher · View at Google Scholar
  91. M. Delville, T. K. Sigdel, C. Wei et al., “A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation,” Science Translational Medicine, vol. 6, no. 256, Article ID 256ra136, 2014. View at Publisher · View at Google Scholar
  92. T. Plesner, M. Ploug, V. Ellis et al., “The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils,” Blood, vol. 83, no. 3, pp. 808–815, 1994. View at Google Scholar · View at Scopus
  93. A. Estreicher, J. Muhlhauser, J.-L. Carpentier, L. Orci, and J.-D. Vassalli, “The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes,” Journal of Cell Biology, vol. 111, no. 2, pp. 783–792, 1990. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Nykjaer, B. Moller, and R. F. Todd III et al., “Urokinase receptor. an activation antigen in human T lymphocytes,” The Journal of Immunology, vol. 152, pp. 505–516, 1994. View at Google Scholar
  95. ES. Barnathan, A. Kuo, K. Kariko et al., “Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA,” Blood, vol. 76, pp. 1795–1806, 1990. View at Google Scholar
  96. M. Thunø, B. MacHo, and J. Eugen-Olsen, “SuPAR: the molecular crystal ball,” Disease Markers, vol. 27, no. 3-4, pp. 157–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Florquin, J. G. van den Berg, D. P. Olszyna et al., “Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia,” Kidney International, vol. 59, no. 6, pp. 2054–2061, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Wei, C. C. Moller, M. M. Altintas et al., “Modification of kidney barrier function by the urokinase receptor,” Nature Medicine, vol. 14, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Lyngbæk, J. L. Marott, T. Sehestedt et al., “Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score,” International Journal of Cardiology, vol. 167, no. 6, pp. 2904–2911, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Persson, G. Engström, H. Björkbacka, and B. Hedblad, “Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study,” Atherosclerosis, vol. 220, no. 2, pp. 502–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. J. M. Spinale, L. H. Mariani, S. Kapoor et al., “A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease,” Kidney International, vol. 87, no. 3, pp. 564–574, 2015. View at Publisher · View at Google Scholar · View at Scopus
  102. B. Meijers, R. J. H. Maas, B. Sprangers et al., “The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis,” Kidney International, vol. 85, no. 3, pp. 636–640, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Sinha, J. Bajpai, S. Saini et al., “Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children,” Kidney International, vol. 85, no. 3, pp. 649–658, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Wada, M. Nangaku, S. Maruyama et al., “A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease,” Kidney International, vol. 85, no. 3, pp. 641–648, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis,” Nature Medicine, vol. 17, no. 8, pp. 952–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. D. Cathelin, S. Placier, M. Ploug et al., “Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice,” Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1662–1668, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. B. Zhang, S. Xie, W. Shi, and Y. Yang, “Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria,” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1746–1755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Trimarchi, R. Canzonieri, A. Muryan et al., “Podocyturia: a clue for the rational use of amiloride in Alport renal disease,” Case Reports in Nephrology, vol. 2016, Article ID 1492743, 4 pages, 2016. View at Publisher · View at Google Scholar
  109. H. Trimarchi, M. Forrester, F. Lombi et al., “Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease: the potential roles of plasmin and uPAR,” Case Reports in Nephrology, vol. 2014, Article ID 854521, 6 pages, 2014. View at Publisher · View at Google Scholar
  110. R. Coppo, R. Camilla, M. G. Porcellini et al., “Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study,” Nephrology Dialysis Transplantation, vol. 27, no. 5, pp. 1902–1910, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Walters, F. A. Choudhury, and B. Nanayakkara, “A case of nephrotic syndrome, showing evidence of response to saquinavir,” Case Reports in Nephrology, vol. 2015, Article ID 512549, 3 pages, 2015. View at Publisher · View at Google Scholar
  112. S. C. Palmer, M. Sciancalepore, and G. F. M. Strippoli, “Trial quality in nephrology: how are we measuring up?” American Journal of Kidney Diseases, vol. 58, no. 3, pp. 335–337, 2011. View at Google Scholar